This post was originally published on this site
Valneva said it had agreed to increase the principal amount of its existing $60 million debt financing agreement with up to an additional $40 million with Deerfield and OrbiMed.
This extension would provide Valneva immediate access to $20 million, with an additional $20 million available upon potential conditional approval of its inactivated COVID-19 vaccine candidate, VLA2001, by the European Medicines Agency, said the company.
